Fast Track’s reverSASP Therapeutics signs aging-disease drug R&D pact with GMO Internet Group

Reuters2026/09/02 23:39

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fast Track Initiative portfolio company reverSASP Therapeutics signed a joint R&D deal with GMO Internet Group on aging-related disease drugs.
Partnership targets development and commercialization of reverSASP’s GLS1 inhibitor program, using GMO’s AI and machine-learning capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fast Track Initiative Inc published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fast Track’s reverSASP Therapeutics signs aging-disease drug R&D pact with GMO Internet Group

You may also like

Crypto prices